SYDNEY--Neuren Pharmaceuticals shares gained after its U.S. partner signaled global net sales of the Daybue treatment for Rett Syndrome could reach US$700 million in 2028. Shares were recently up 8.3% ...

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week. Three ASX shares that ...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares were out of form on Tuesday after getting caught up in the market selloff. The ...

Kirstie Cummings, Ph.D., an assistant professor in the Department of Neurobiology, was recently honored with the Heersink School of Medicine's Featured Discovery Award. She was recognized alongside ...

Acadia Pharmaceuticals committed a lot of money for rights to Daybue, which in the biotech’s hands became the first FDA-approved drug for the rare neurological disorder Rett syndrome. That approval ...

Neuren Pharmaceuticals Ltd.’s NNZ-2591 met the primary endpoints in a phase II trial in children with Angelman syndrome, with improvements seen in clinically important aspects of the disease, ...

Neuren’s NNZ-2591 receives a Rare Pediatric Disease Designation from US FDA This could lead to a Priority Review Voucher if drug is approved Neuren is also preparing for a key FDA meeting, building on ...

Principal Investigator Cassandra Newsom, Psy.D., director of the Translational Research Core in Autism and Neurodevelopment of Civitan International Research Center, has completed participation in ...